| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 136.00 | 2.4% |
| Total Income | 136.00 | 2.4% |
| Expenditure | 305.00 | 8.1% |
| PBT | -184.00 | 22.9% |
| Net Profit | -185.00 | 22.4% |
| OPM | — | |
| NPM | — | |
| EPS | -1.84 | 17.2% |
Ultragenyx Reports Q1 2026 Revenue of $136 Million
06 May 2026 · 6 May, 1:42 am
Summary
Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter ended March 31, 2026. The company's total revenue for the first quarter was $136 million. Ultragenyx reaffirmed its full year 2026 total revenue guidance of $730 million to $760 million. The company is also reaffirming its 2026 financial guidance and remains on track to profitability in 2027.
Key Highlights
- 1
Ultragenyx reported first quarter total revenue of $136 million.
- 2
Crysvita revenue for the first quarter was $93 million.
- 3
Dojolvi revenue in the first quarter was $18 million.
- 4
Evkeeza revenue in the first quarter was $18 million, driven by increased demand.
- 5
Mepsevii revenue in the first quarter was $7 million.
- 6
The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, excluding potential new product launches.
- 7
The company remains on track to profitability in 2027.
Management Comments
Emil D. Kakkis
M.D., Ph.D.
"This is an important year for Ultragenyx with two BLAs under review and our Angelman Phase 3 readout coming soon. We have the opportunity to meaningfully accelerate our consistent commercial revenue growth over the last few years as we prepare for two potential gene therapy approvals and launches in two urgent diseases without any approved therapies," "The latest long-term GTX-102 Phase 1/2 data further support the potential of the program, as it heads toward Phase 3 results later this year."
Informational and educational content only. Not investment advice.